NEW YORK, Jan. 21 (GenomeWeb News) - Freemont, Calif.-based Ciphergen Biosystems today announced the expansion of its existing license agreement with Genencor International.
Under the expanded terms of the agreement, Ciphergen said it now has exclusive, worldwide right to use Genencor's Hydrophobic Charge Induction chromatography technology for the production of its MEP HyperCel-brand chromatographic sorbents as well as MEP membranes, both of which are used in the capture, purification, and production of monoclonal antibodies. Ciphergen has the right to both distribute products based on this technology through its own channels and third parties. The agreement also conditionally allows Ciphergen to sub-contract MEP Hypercel manufacturing rights under the license to third parties.
Financial details were not disclosed.